Product Description
VTP-300 is an immunotherapeutic agent that Vaccitech intends to administer in combination with a low-dose anti-PD-1 antibody, to counterbalance the immune suppression and T cell exhaustion in the liver caused by CHB. (Sourced from: https://www.vaccitech.co.uk/pipeline/)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Arbutus Biopharma
Company Location: BURNABY A1 V5J 5J8
Company CEO: William Collier
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Hepatitis B, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACTRN12622000317796 | P2 |
Recruiting |
Hepatitis B, Chronic |
2022-08-31 |